You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
永泰生物-B(6978.HK)盤中逆勢拉昇漲超44%
格隆匯 09-21 11:01
格隆匯9月21日丨港股市場生物醫藥B類股今日多數下跌,但自研型創新藥企永泰生物-B(6978.HK)盤中逆勢拉昇一度漲超44%報4.9港元。永泰生物旗下EAL®(擴增活化的淋巴細胞)、CAR-T-19注射液、6B11-OCIK注射液目前已處於臨牀試驗階段,據瞭解,臨牀試驗進展順利。其核心在研產品EAL®用於預防肝癌術後復發適應症的II期臨牀試驗已完成417名目標患者的入組工作(2022年半年報數據),並取得了顯著的臨牀效果。據悉,經過EAL®治療後,患者的生存期明顯延長,生活質量也得到了大幅提高。作為中國首款獲准進入II期臨牀試驗、適應症為實體瘤的細胞免疫治療產品,EAL®的先發優勢尤為明顯,目前在該領域內暫無任何競爭對手。由於新冠疫情的衝擊,EAL®臨牀試驗的推動比原計劃延後,但據目前的進展,預計很快可以看到該產品在肝癌治療領域的公開數據。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account